ArticleHaematologica2021

mTOR inhibitors sensitize multiple myeloma cells to venetoclax via IKZF3- and Blimp-1-mediated BCL-2 upregulation.

Naoki Osada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.